Table Of Contents
Chapter 1. Methodology And Scope
1.1. Market Segmentation And Scope
1.1.1. Segment Definitions
1.1.1.1. Product Segment
1.1.1.2. Technique Segment
1.1.1.3. Type Segment
1.1.1.4. Application Segment
1.1.1.5. Scale Of Operations Segment
1.2. Information Procurement
1.2.1. Market Formulation & Data Visualization
1.2.2. Data Validation & Publishing
1.3. Research Assumptions
1.4. Research Methodology
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details Of Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.1.1. Approach 1: Commodity Flow Approach
1.8. List Of Secondary Sources
1.9. Global Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Cancer Type And Product Snapshot
2.3. Technology And End-Use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Hemato Oncology Testing Market Variables And Trends
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Impact Analysis
3.2.1.1. Increasing Prevalence Of Lymphoma & Myeloma
3.2.1.2. Growing Demand For Personalized Therapy
3.2.1.3. Availability Of Advanced Molecular Techniques For Hemato-Oncology Diagnostics
3.2.1.4. Increasing Drug-Diagnostics Co-Development
3.2.2. Market Restraint Impact Analysis
3.2.2.1. Unfavorable Reimbursement Scenario.
3.3. Impact Of The Covid-19 Pandemic
3.4. Industry Analysis Tools
3.4.1. Porter’s Analysis
3.4.2. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
Chapter 4. Hemato Oncology Testing Market: Cancer Type Estimates & Trend Analysis
4.1. Cancer Type Movement Analysis & Market Share, 2022 & 2030
4.2. Hemato Oncology Testing Market Estimates & Forecast, By Cancer Type (USD Million)
4.3. Leukemia
4.3.1. Global Leukemia Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.3.2. Acute Myeloid Leukemia (AML)
4.3.2.1. Global Acute Myeloid Leukemia (AML) Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.3.3. Acute Lymphocytic Leukemia (ALL)
4.3.3.1. Global Acute Lymphocytic Leukemia (ALL) Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.3.4. Chronic Lymphocytic Leukemia
4.3.4.1. Global Chronic Lymphocytic Leukemia Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.3.5. Chronic Myeloid Leukemia
4.3.5.1. Global Chronic Myeloid Leukemia Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.4. Lymphoma
4.4.1. Global Lymphoma Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.4.2. Non-Hodgkin Lymphoma
4.4.2.1. Global Non-Hodgkin Lymphoma Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.4.3. Hodgkin Lymphoma
4.4.3.1. Global Hodgkin Lymphoma Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.5. Myeloproliferative Neoplasms
4.5.1. Global Myeloproliferative Neoplasms Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.5.2. Polycythemia Vera (PV)
4.5.2.1. Global Polycythemia Vera (PV) Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.5.3. Essential Thrombocythemia (ET)
4.5.3.1. Global Essential Thrombocythemia (ET) Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.5.4. Myelofibrosis (MF)
4.5.4.1. Global Myelofibrosis (MF) Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.6. Others Cancers
4.6.1. Global Others Cancers Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 5. Hemato Oncology Testing Market: Product Estimates & Trend Analysis
5.1. Product Movement Analysis & Market Share, 2022 & 2030
5.2. Hemato Oncology Testing Market Estimates & Forecast, By Product (USD Million)
5.3. Assay Kits And Reagents
5.3.1. Global Assay Kits And Reagents Market Estimates And Forecasts, 2018 – 2030 (USD Million)
5.4. Services
5.4.1. Global Services Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 6. Hemato Oncology Testing Market: Technology Estimates & Trend Analysis
6.1. Technology Movement Analysis & Market Share, 2022 & 2030
6.2. Hemato Oncology Testing Market Estimates & Forecasts, By Technology (USD Million)
6.3. PCR
6.3.1. Global PCR Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.2. Real-Time qPCR
6.3.2.1. Global Real-Time qPCR Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.3. Digital PCR
6.3.3.1. Global Digital PCR Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4. Ihc
6.4.1. Global IHC Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.5. Ngs
6.5.1. Global NGS Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.6. Cytogenetics
6.6.1. Global Cytogenetics Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.7. Other Technologies
6.7.1. Global Other Technologies Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 7. Hemato Oncology Testing Market: Application Estimates & Trend Analysis
7.1. Application Movement Analysis & Market Share, 2022 & 2030
7.2. Hemato Oncology Testing Market Estimates & Forecast, By Application (USD Million)
7.3. Hospitals
7.3.1. Global Hospitals Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.4. Academic & Research Institutes
7.4.1. Global Academic & Research Institutes Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.5. Others
7.5.1. Global Others Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 8. Hemato Oncology Testing Market: Regional Estimates And Trend Analysis
8.1. Hemato Oncology Testing Market: Regional Outlook
8.2. North America
8.2.1. North America Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Competitive Scenario
8.2.2.3. Regulatory Framework
8.2.2.4. U.S. Hemato Oncology Testing Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Competitive Scenario
8.2.3.3. Regulatory Framework
8.2.3.4. Canada Hemato Oncology Testing Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3. Europe
8.3.1. Europe Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.2. Germany
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. Germany Hemato Oncology Testing Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. UK Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. France Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Competitive Scenario
8.3.5.3. Regulatory Framework
8.3.5.4. Italy Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Competitive Scenario
8.3.6.3. Regulatory Framework
8.3.6.4. Spain Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.7. Russia
8.3.7.1. Key Country Dynamics
8.3.7.2. Competitive Scenario
8.3.7.3. Regulatory Framework
8.3.7.4. Russia Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Competitive Scenario
8.3.8.3. Regulatory Framework
8.3.8.4. Denmark Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Competitive Scenario
8.3.9.3. Regulatory Framework
8.3.9.4. Sweden Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Competitive Scenario
8.3.10.3. Regulatory Framework
8.3.10.4. Norway Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. Japan Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. China Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. India Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.5. South Korea
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. South Korea Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.6. Singapore
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Singapore Asia Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.7. Australia
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. Australia Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.8. Thailand
8.4.8.1. Key Country Dynamics
8.4.8.2. Competitive Scenario
8.4.8.3. Regulatory Framework
8.4.8.4. Thailand Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Brazil Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Mexico Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. Argentina Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.6. MEA
8.6.1. MEA Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. South Africa Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Saudi Arabia Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. UAE Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Kuwait Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 9. Hemato Oncology Testing Market: Competitive Landscape
9.1. Participant Categorization
9.1.1. Amoy Diagnostics Co. Ltd
9.1.1.1. Overview
9.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.1.3. Product Benchmarking
9.1.1.4. Strategic Initiatives
9.1.2. EntroGen
9.1.2.1. Overview
9.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.2.3. Product Benchmarking
9.1.2.4. Strategic Initiatives
9.1.3. Cepheid
9.1.3.1. Overview
9.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.3.3. Product Benchmarking
9.1.3.4. Strategic Initiatives
9.1.4. ASURAGEN, INC
9.1.4.1. Overview
9.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.4.3. Product Benchmarking
9.1.4.4. Strategic Initiatives
9.1.5. ArcherDX, Inc.
9.1.5.1. Overview
9.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.5.3. Product Benchmarking
9.1.5.4. Strategic Initiatives
9.1.6. Invivoscribe, Inc.
9.1.6.1. Overview
9.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.6.3. Product Benchmarking
9.1.6.4. Strategic Initiatives
9.1.7. Adaptive Biotechnologies
9.1.7.1. Overview
9.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.7.3. Product Benchmarking
9.1.7.4. Strategic Initiatives
9.1.8. Abbott
9.1.8.1. Overview
9.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.8.3. Product Benchmarking
9.1.8.4. Strategic Initiatives
9.1.9. ARUP Laboratories
9.1.9.1. Overview
9.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.9.3. Product Benchmarking
9.1.9.4. Strategic Initiatives
9.1.10. Illumina, Inc.
9.1.10.1. Overview
9.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.10.3. Product Benchmarking
9.1.10.4. Strategic Initiatives
9.1.11. Bio-Rad Laboratories, Inc.
9.1.11.1. Overview
9.1.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.11.3. Product Benchmarking
9.1.11.4. Strategic Initiatives
9.2. Participant’s Overview
9.3. Financial Performance
9.4. Product Benchmarking
9.5. Company Market Share Analysis, 2022
9.6. Strategy Mapping
9.6.1. Expansion
9.6.2. Acquisition
9.6.3. Product/Service Launch
9.6.4. Others
Chapter 10. Analyst View
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/